Skip to main content
Contact Us
Subscribe
E-Edition
44°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alx Oncology Holdings Inc
(NQ:
ALXO
)
1.450
+0.030 (+2.11%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Alx Oncology Holdings Inc
< Previous
1
2
Next >
ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024
December 12, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer
December 10, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 26, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Holdings Inc. (NASDAQ: ALXO) Leading the Way in Friday Trading Based on Percentage Gain
December 08, 2023
Via
Investor Brand Network
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
November 14, 2024
Dr. Sandler brings more than 30 years of experience as a distinguished leader in oncology and drug development
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 07, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Announces November Investor Conference Participation
November 04, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
November 01, 2024
Poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational CD47 blocker, in combination with zanidatamab, an investigational dual...
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
September 09, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
September 04, 2024
Clinical study is evaluating ALX Oncology’s investigational CD47-blocking therapeutic with Sanofi’s approved CD38 monoclonal antibody in patients with multiple myeloma
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 08, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
August 06, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer
July 31, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
July 31, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
June 02, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
May 29, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Appoints Allison Dillon as Chief Business Officer
May 07, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer
April 30, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
April 24, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
April 09, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 07, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
March 05, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Announces November Investor Conference Participation
November 01, 2023
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 10, 2023
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Announces Pricing of Public Offering
October 05, 2023
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Announces Proposed Public Offering
October 04, 2023
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Holdings Inc. (NASDAQ: ALXO) is One of Tuesday Morning’s Most Active Stocks
October 03, 2023
Via
Investor Brand Network
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.